Loading…

Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study

The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use. We prospectively studied childr...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 2008-03, Vol.121 (3), p.e481-e488
Main Authors: Glaser, Nicole S, Styne, Dennis M, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3
cites cdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3
container_end_page e488
container_issue 3
container_start_page e481
container_title Pediatrics (Evanston)
container_volume 121
creator Glaser, Nicole S
Styne, Dennis M
Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group
description The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use. We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables. Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children.
doi_str_mv 10.1542/peds.2007-1535
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70360397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70360397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</originalsourceid><addsrcrecordid>eNpdkc1v1DAQxS0EotvClSOyOJQL2frbTm_VUgrSIqoC4mh57Unjkk22tlPU_76JdiUQp5nDb97Mm4fQG0qWVAp2toOQl4wQXVHJ5TO0oKQ2lWBaPkcLQjitBCHyCB3nfEcIEVKzl-iIGqZ0resFitcJQvQl9re4tIDX8Td0sR2GgIcG38A25hyHHscer9rYhQQ9_hVLi6-Se4D8Hn-MGVyGc3yBr9OQdzBpPcAH_HXsSvTQF0j4exnD4yv0onFdhteHeoJ-frr8sfpcrb9dfVldrCvPFSmVU8EzYYzUSgRJN7o2AKLZOAZMBOUcJ15Izx31TAemjCKydhultGlA-cBP0Oled5eG-xFysZMHD13nehjGbDWZ9vBaT-C7_8C7YUz9dJtlzHCmuJETtNxDfjKXEzR2l-LWpUdLiZ0TsHMCdk7AzglMA28PquNmC-Evfnj5BJztgTbetn9iglkhupKiz_-0lFHLLQhD-RNtp5K_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>228326385</pqid></control><display><type>article</type><title>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</title><source>EZB Electronic Journals Library</source><creator>Glaser, Nicole S ; Styne, Dennis M ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creator><creatorcontrib>Glaser, Nicole S ; Styne, Dennis M ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group ; for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</creatorcontrib><description>The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use. We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables. Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2007-1535</identifier><identifier>PMID: 18267979</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>United States: Am Acad Pediatrics</publisher><subject>Adolescent ; Age Factors ; Antithyroid Agents - administration &amp; dosage ; Child ; Children &amp; youth ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Graves Disease - diagnosis ; Graves Disease - drug therapy ; Hormones ; Humans ; Logistic Models ; Male ; Multivariate Analysis ; Pediatrics ; Predictive Value of Tests ; Propylthiouracil - administration &amp; dosage ; Prospective Studies ; Risk Assessment ; Severity of Illness Index ; Sex Factors ; Studies ; Thyroid diseases ; Thyroid Function Tests ; Treatment Outcome</subject><ispartof>Pediatrics (Evanston), 2008-03, Vol.121 (3), p.e481-e488</ispartof><rights>Copyright American Academy of Pediatrics Mar 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</citedby><cites>FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18267979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glaser, Nicole S</creatorcontrib><creatorcontrib>Styne, Dennis M</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</creatorcontrib><title>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use. We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables. Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children.</description><subject>Adolescent</subject><subject>Age Factors</subject><subject>Antithyroid Agents - administration &amp; dosage</subject><subject>Child</subject><subject>Children &amp; youth</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graves Disease - diagnosis</subject><subject>Graves Disease - drug therapy</subject><subject>Hormones</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Multivariate Analysis</subject><subject>Pediatrics</subject><subject>Predictive Value of Tests</subject><subject>Propylthiouracil - administration &amp; dosage</subject><subject>Prospective Studies</subject><subject>Risk Assessment</subject><subject>Severity of Illness Index</subject><subject>Sex Factors</subject><subject>Studies</subject><subject>Thyroid diseases</subject><subject>Thyroid Function Tests</subject><subject>Treatment Outcome</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNpdkc1v1DAQxS0EotvClSOyOJQL2frbTm_VUgrSIqoC4mh57Unjkk22tlPU_76JdiUQp5nDb97Mm4fQG0qWVAp2toOQl4wQXVHJ5TO0oKQ2lWBaPkcLQjitBCHyCB3nfEcIEVKzl-iIGqZ0resFitcJQvQl9re4tIDX8Td0sR2GgIcG38A25hyHHscer9rYhQQ9_hVLi6-Se4D8Hn-MGVyGc3yBr9OQdzBpPcAH_HXsSvTQF0j4exnD4yv0onFdhteHeoJ-frr8sfpcrb9dfVldrCvPFSmVU8EzYYzUSgRJN7o2AKLZOAZMBOUcJ15Izx31TAemjCKydhultGlA-cBP0Oled5eG-xFysZMHD13nehjGbDWZ9vBaT-C7_8C7YUz9dJtlzHCmuJETtNxDfjKXEzR2l-LWpUdLiZ0TsHMCdk7AzglMA28PquNmC-Evfnj5BJztgTbetn9iglkhupKiz_-0lFHLLQhD-RNtp5K_</recordid><startdate>20080301</startdate><enddate>20080301</enddate><creator>Glaser, Nicole S</creator><creator>Styne, Dennis M</creator><creator>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creator><general>Am Acad Pediatrics</general><general>American Academy of Pediatrics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20080301</creationdate><title>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</title><author>Glaser, Nicole S ; Styne, Dennis M ; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Age Factors</topic><topic>Antithyroid Agents - administration &amp; dosage</topic><topic>Child</topic><topic>Children &amp; youth</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graves Disease - diagnosis</topic><topic>Graves Disease - drug therapy</topic><topic>Hormones</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Multivariate Analysis</topic><topic>Pediatrics</topic><topic>Predictive Value of Tests</topic><topic>Propylthiouracil - administration &amp; dosage</topic><topic>Prospective Studies</topic><topic>Risk Assessment</topic><topic>Severity of Illness Index</topic><topic>Sex Factors</topic><topic>Studies</topic><topic>Thyroid diseases</topic><topic>Thyroid Function Tests</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glaser, Nicole S</creatorcontrib><creatorcontrib>Styne, Dennis M</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</creatorcontrib><creatorcontrib>for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glaser, Nicole S</au><au>Styne, Dennis M</au><au>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</au><aucorp>Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group</aucorp><aucorp>for the Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2008-03-01</date><risdate>2008</risdate><volume>121</volume><issue>3</issue><spage>e481</spage><epage>e488</epage><pages>e481-e488</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>The optimal treatment for Graves' disease in children is controversial. Antithyroid medications are often used initially, but many children eventually require alternative therapies. We evaluated predictors of remission after 2 years of antithyroid medication use. We prospectively studied children who had Graves' disease and were treated with antithyroid medications. We compared children who achieved remission after 2 years with those who had persistent disease to determine which variables were associated with remission; multiple logistic regression and binary recursive partitioning analyses were used to evaluate interactions among predictive variables. Of 51 children who completed the study, 15 (29%) achieved remission. Children who achieved remission had lower thyroid hormone concentrations at presentation than those with persistent disease (free thyroxine: 6.17 +/- 3.10 vs 9.86 +/- 7.54 ng/dL; total triiodothyronine: 431 +/- 175 vs 561 +/- 225 ng/dL). Children who achieved remission were also more likely to be euthyroid within 3 months of initiating propylthiouracil (82% vs 29%). Binary recursive partitioning analysis identified rapid achievement of euthyroid status after initiation of propylthiouracil, lower initial triiodothyronine, and older age as significant predictors of remission. CONCLUSIONS; Thyroid hormone concentrations at diagnosis, age, and initial response to propylthiouracil can be used to stratify patients according to the likelihood of remission after 2 years of antithyroid medication use. These data provide a useful guide for clinical decision-making regarding Graves' disease in children.</abstract><cop>United States</cop><pub>Am Acad Pediatrics</pub><pmid>18267979</pmid><doi>10.1542/peds.2007-1535</doi></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 2008-03, Vol.121 (3), p.e481-e488
issn 0031-4005
1098-4275
language eng
recordid cdi_proquest_miscellaneous_70360397
source EZB Electronic Journals Library
subjects Adolescent
Age Factors
Antithyroid Agents - administration & dosage
Child
Children & youth
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Graves Disease - diagnosis
Graves Disease - drug therapy
Hormones
Humans
Logistic Models
Male
Multivariate Analysis
Pediatrics
Predictive Value of Tests
Propylthiouracil - administration & dosage
Prospective Studies
Risk Assessment
Severity of Illness Index
Sex Factors
Studies
Thyroid diseases
Thyroid Function Tests
Treatment Outcome
title Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20the%20Likelihood%20of%20Remission%20in%20Children%20With%20Graves'%20Disease:%20A%20Prospective,%20Multicenter%20Study&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Glaser,%20Nicole%20S&rft.aucorp=Organization%20of%20Pediatric%20Endocrinologists%20of%20Northern%20California%20Collaborative%20Graves'%20Disease%20Study%20Group&rft.date=2008-03-01&rft.volume=121&rft.issue=3&rft.spage=e481&rft.epage=e488&rft.pages=e481-e488&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2007-1535&rft_dat=%3Cproquest_cross%3E70360397%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c360t-a6dc24885764d51b798ee4fba2e24d6aa30c45c3a1c27d2686059ab6678fe6cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=228326385&rft_id=info:pmid/18267979&rfr_iscdi=true